J75 Stock Overview
Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Kineta, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.55 |
| 52 Week High | US$2.50 |
| 52 Week Low | US$0.31 |
| Beta | 0 |
| 1 Month Change | 21.65% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -76.10% |
Recent News & Updates
Recent updates
Shareholder Returns
| J75 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.7% | 2.1% | -1.0% |
| 1Y | n/a | -22.4% | 2.0% |
Return vs Industry: Insufficient data to determine how J75 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how J75 performed against the German Market.
Price Volatility
| J75 volatility | |
|---|---|
| J75 Average Weekly Movement | 27.8% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: J75's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine J75's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 12 | n/a | kinetabio.com |
Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug.
Kineta, Inc. Fundamentals Summary
| J75 fundamental statistics | |
|---|---|
| Market cap | €5.91m |
| Earnings (TTM) | -€13.10m |
| Revenue (TTM) | €5.06m |
1.2x
P/S Ratio-0.5x
P/E RatioIs J75 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| J75 income statement (TTM) | |
|---|---|
| Revenue | US$5.44m |
| Cost of Revenue | US$9.02m |
| Gross Profit | -US$3.58m |
| Other Expenses | US$10.52m |
| Earnings | -US$14.10m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.24 |
| Gross Margin | -65.80% |
| Net Profit Margin | -259.08% |
| Debt/Equity Ratio | 25.2% |
How did J75 perform over the long term?
See historical performance and comparison